Biocytogen 

About Us

>

Yuelei Shen Ph.D, Chairman & CEO

Dr. Yuelei Shen is the founder, President and CEO of Beijing Biocytogen Co., LTD and Biocytogen LLC. Dr. Shen got his Ph.D degree from University of Massachusetts School of Medicine in 2003. He did his postdoc training in New York University School of Medicine from 2003-2008 with Dr. Dan R. Littman. In 2008, Dr. Shen founded Biocytogen LLC in Worcester, MA and in 2009, he moved back to Beijing, China and established Beijing Biocytogen Co., LTD. In 2015, Biocytogen Jiangsu Co.,Ltd was set up and in 2018, Biocytogen Boston Lab in Wakefield started operation. In past 10 years, especially from 2015, Biocytogen has successfully transformed its business from a custom gene-targeting model provider only into a unique, comprehensive and dynamic system covering innovative animal model generation, large scale production, pharmacology study and therapeutic antibody discovery service, to promote drug discovery more efficiently. Dr. Shen is honored as member of “Thousand Talents Program” and “100 science andtechnology leading talents of Beijing”.

Qingcong Lin Ph.D., Senior Vice President of Biocytogen and CEO of Biocytogen Boston

Dr. Qingcong Lin is Senior Vice President of Biocytogen and CEO of Biocytogen Boston, focusing on developing gene-specific humanized mouse models and immune system humanized animal models using cutting-edge CRISPR-Cas9 technology for immuno-oncology drug candidate preclinical pharmacology and toxicity assessment. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group, responsible for biologic drug development. Dr. Lin has extensive expertise in multiple drug R&D and therapeutic areas, including cell biology, molecular biology, molecular genetics, genetically engineered mouse tumor model, therapeutic antibody development, hybridoma antibody and human phage antibody library construction, antibody engineering, antibody humanization, affinity maturation and optimization, and mammalian antibody expression and production. Prior to joining Sheongen, he worked in Pfizer as a principal scientist and group leader of antibody engineering group. Before joining Pfizer, he worked for Wyeth and Harvard Medical School as Director of Genetic Engineering Lab of Genetics and Genomics Research Center. Dr. Lin received Ph.D. degree of Molecular Cell Biology from Albert-Einstein College of Medicine and completed his postdoctoral training on tumor molecular genetics in Albert-Einstein College of Medicine and Harvard Medical School.

James Jin Ph. D., Vice President of Biocytogen

Dr. James Jin received his PhD of virology at Wuhan University in 1997. He had his postdoctoral training at Colorado State University. He worked as a research assistant professor in University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a senior scientist. Dr. Jin joined Biocytogen as the director of technology in 2011, and then was promoted to vice president in 2012. His research covers virology, immunology, proteomics, protein structure, human stem cell, and gene-targeting animal model.

Chaoshe Guo Vice President of Marketing

Dr. Guo received a doctoral degree in Biochemistry in November, 2003, where he worked on the functional study of molecular chaperones via biochemistry, structural biology, and gene knockout mouse models. In 2005-2013, Dr. Guo has focused on Hedgehog signaling and its role in cardiovascular system and blood system development through his joint appointment in the Department of Molecular and Cellular Biology at Harvard University and Boston Children's Hospital/Harvard Medical School. His research has been published in JCI, Development, and other highly reputed journals. Dr. Guo is also experienced in animal model production and phenotype analysis. In October, 2013, Dr. Guo served as the Senior R&D Director and Key Account Manager of Beijing Biocytogen Co., Ltd, and also served as the Vice President of Marketing in June, 2015.

Yi Yang Ph.D., Director of Antibody Research and Development Division

Dr. Yi Yang graduated from Fudan University with Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from University of Connecticut Health Center and completed his postdoctoral training in New York University School of Medicine in Dr. Dan R. Littman’s research group. Dr. Yang worked as a tenure-track Assistant Professor at the Department of Microbiology and Immunology in Medical University of South Carolina from 2014 to 2016. In 2016, he returned to China and joined Biocytogen. Taking good advantage of his research background in immunology, he studied the newly discovered immune regulation of Th17 cells and intestinal microbial immunity, and published a series of paper on Nature, Science and Cell.

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud